GURMIT SINGH: Open Payments
NPI 1598881286 · STANFORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$733 in 27 payments from 12 companies in 2025. Trend: 2023 $355 · 2024 $503 · 2025 $733
Food & beverage: $733
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $201 |
| Medtronic, Inc. | 1 | $111 |
| Stemline Therapeutics Inc. | 1 | $107 |
| GlaxoSmithKline, LLC. | 1 | $99 |
| E.R. Squibb & Sons, L.L.C. | 3 | $47 |
| Exelixis Inc. | 2 | $39 |
| Caris MPI, Inc. | 1 | $32 |
| BeiGene USA, Inc. | 1 | $26 |
| Incyte Corporation | 1 | $20 |
| PFIZER INC. | 1 | $18 |
Products named: PLUVICTO, MAZOR X SYSTEM, ELZONRIS, OJJAARA, SCEMBLIX, CABOMETYX, LUTATHERA, MI CANCER SEEK.
Industry payments across CA — which companies pay providers there.
